Subscribe Now Subscribe Today
Science Alert
Curve Top
International Journal of Pharmacology
  Year: 2010 | Volume: 6 | Issue: 6 | Page No.: 784-795
DOI: 10.3923/ijp.2010.784.795
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Molecular Targets in the Development of Antidiabetic Drugs

Adel S. Al- Zubairi and Eltayeb Elamin M. Eid

Type 2 diabetes mellitus (T2DM) is a worldwide public health problem. The fact that the existing treatments have limitations either because of their side effects as hypoglycaemia and weight gain or their other complications necessitate the need for development of new therapies for glycemic control. The therapeutic approachs represented by the incretin-based therapies, namely the dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide-1 (GLP-1) analogues/mimetics, offer a new therapeutic means for treatment of T2DM, in addition to other several even newer therapies in development. A great attention has been focused by many researchers on a number of potential molecular targets in fat cells or adipocytes, as the adipokines. In this article we will review the development of the possible molecular targets for the currently available antidiabetic agents with particular emphasis on incretin-based therapeutic targets as well as molecular targets in adipocytes and other future therapies.
PDF Fulltext XML References Citation Report Citation
  •    Lambda Phage Nanoparticles for Targetomics
  •    A Review of Antisense Therapeutic Interventions for Molecular Biological Targets in Various Diseases
  •    Anticancer and Antimicrobial Activities of Zerumbone from the Rhizomes of Zingiber zerumbut
  •    Anticancer Activity of Natural Compound (Zerumbone) Extracted from Zingiber zerumbet in Human HeLa Cervical Cancer Cells
How to cite this article:

Adel S. Al- Zubairi and Eltayeb Elamin M. Eid, 2010. Molecular Targets in the Development of Antidiabetic Drugs. International Journal of Pharmacology, 6: 784-795.

DOI: 10.3923/ijp.2010.784.795


16 September, 2010
xingang yao :
this paper collects the currents promising drug targets.but not the total.this is very good .

the defect is this paper not mention the defects of some drug targets




Curve Bottom